Mixed fortunes for Roche’s Avastin; Xeloda recommended by EU

Article | 26 February 2010

Print This

There was both good and bad news this week for Roche’s top revenue source, cancer drug Avastin. Sales of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in